Skip to main content
Journal cover image

Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas.

Publication ,  Journal Article
Geradts, J; Andriko, JW; Abbondanzo, SL
Published in: Am J Clin Pathol
June 1998

The products of the MTS1/CDKN2 and retinoblastoma (RB) tumor suppressor genes, p16 and pRB, act as agonists in controlling the late G1 cell cycle checkpoint. Inactivation of either gene occurs in a wide range of human malignant neoplasms. Data on the expression of both genes in the same set of malignant lymphoid neoplasms are scarce. We studied the p16/pRB pathway in low-grade and high-grade non-Hodgkin's lymphomas, using immunohistochemical techniques. Paraffin sections of 9 reactive lymph nodes and 43 low-grade and 60 high-grade malignant lymphomas were reacted with antibodies against pRB and p16. All benign lymph nodes showed a normal pattern of RB and MTS1/CDKN2 expression. Of 101 evaluable lymphomas, only a single high-grade tumor displayed loss of RB reactivity. Loss of p16 was identified in 14 of 55 evaluable high-grade lymphomas but not in any of the low-grade lesions. All but 3 of the RB- and p16-negative cases were diffuse large cell lymphomas, for an abnormality rate of 55% in this category. While loss of RB function was a rare event in human lymphomagenesis, p16 was absent in some 25% of high-grade non-Hodgkin's lymphomas; diffuse large cell lymphomas were the primary target of tumor suppressor gene inactivation.

Duke Scholars

Published In

Am J Clin Pathol

DOI

ISSN

0002-9173

Publication Date

June 1998

Volume

109

Issue

6

Start / End Page

669 / 674

Location

England

Related Subject Headings

  • Retinoblastoma Protein
  • Pathology
  • Lymphoma, Non-Hodgkin
  • Lymph Nodes
  • Immunohistochemistry
  • Humans
  • Genes, p16
  • Genes, Retinoblastoma
  • Gene Expression
  • Cyclin-Dependent Kinase Inhibitor p16
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Geradts, J., Andriko, J. W., & Abbondanzo, S. L. (1998). Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. Am J Clin Pathol, 109(6), 669–674. https://doi.org/10.1093/ajcp/109.6.669
Geradts, J., J. W. Andriko, and S. L. Abbondanzo. “Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas.Am J Clin Pathol 109, no. 6 (June 1998): 669–74. https://doi.org/10.1093/ajcp/109.6.669.
Geradts J, Andriko JW, Abbondanzo SL. Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. Am J Clin Pathol. 1998 Jun;109(6):669–74.
Geradts, J., et al. “Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas.Am J Clin Pathol, vol. 109, no. 6, June 1998, pp. 669–74. Pubmed, doi:10.1093/ajcp/109.6.669.
Geradts J, Andriko JW, Abbondanzo SL. Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. Am J Clin Pathol. 1998 Jun;109(6):669–674.
Journal cover image

Published In

Am J Clin Pathol

DOI

ISSN

0002-9173

Publication Date

June 1998

Volume

109

Issue

6

Start / End Page

669 / 674

Location

England

Related Subject Headings

  • Retinoblastoma Protein
  • Pathology
  • Lymphoma, Non-Hodgkin
  • Lymph Nodes
  • Immunohistochemistry
  • Humans
  • Genes, p16
  • Genes, Retinoblastoma
  • Gene Expression
  • Cyclin-Dependent Kinase Inhibitor p16